GARY DUBIN

The development journey for dengue vaccine Qdenga stretches back 60 years: Gary Dubin

Over the past 11 years under Takeda's leadership, the programme has involved 19 clinical trials, encompassing a total of 28000 participants. Notably, one pivotal safety and efficacy study enrolled over 20,000 children aged 4 to 16 and included long-term follow-up. The Lancet recently published the long-term follow-up results for Qdenga. The results showed strong efficacy against both confirmed dengue and, crucially, hospitalised dengue. Over four and a half years, the overall efficacy was 84.1 per cent, regardless of prior dengue exposure.

• Exclusive